Previous work has demonstrated that local injection of sumIL-2 effectively controlled the tumor growth while limit systemic toxicity.59 Therefore, we also revealed that ADAM17 deficiency exhibited a synergistic anti-tumor effect when combined with sumIL-2 treatment. This evidence concerns the gene ADAM17 and neoplasm.